# Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

> **NCT02091375** · PHASE3 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 120 (actual)

## Conditions studied

- Epilepsy
- Dravet Syndrome

## Interventions

- **DRUG:** GWP42003-P 20 mg/kg/day Dose
- **DRUG:** Placebo control

## Key facts

- **NCT ID:** NCT02091375
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03-30
- **Primary completion:** 2015-11-26
- **Final completion:** 2015-11-26
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02091375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02091375, "Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02091375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*